These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 22221940)

  • 1. Follow-up with exercise test of effort-induced ventricular arrhythmias linked to ryanodine receptor type 2 gene mutations.
    Steriotis AK; Nava A; Rampazzo A; Basso C; Thiene G; Daliento L; Folino AF; Rigato I; Mazzotti E; Beffagna G; Carturan E; Corrado D; Bauce B
    Am J Cardiol; 2012 Apr; 109(7):1015-9. PubMed ID: 22221940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening for ryanodine receptor type 2 mutations in families with effort-induced polymorphic ventricular arrhythmias and sudden death: early diagnosis of asymptomatic carriers.
    Bauce B; Rampazzo A; Basso C; Bagattin A; Daliento L; Tiso N; Turrini P; Thiene G; Danieli GA; Nava A
    J Am Coll Cardiol; 2002 Jul; 40(2):341-9. PubMed ID: 12106942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High prevalence of exercise-induced arrhythmias in catecholaminergic polymorphic ventricular tachycardia mutation-positive family members diagnosed by cascade genetic screening.
    Haugaa KH; Leren IS; Berge KE; Bathen J; Loennechen JP; Anfinsen OG; Früh A; Edvardsen T; Kongsgård E; Leren TP; Amlie JP
    Europace; 2010 Mar; 12(3):417-23. PubMed ID: 20106799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flecainide therapy suppresses exercise-induced ventricular arrhythmias in patients with CASQ2-associated catecholaminergic polymorphic ventricular tachycardia.
    Khoury A; Marai I; Suleiman M; Blich M; Lorber A; Gepstein L; Boulos M
    Heart Rhythm; 2013 Nov; 10(11):1671-5. PubMed ID: 23954267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postpacing abnormal repolarization in catecholaminergic polymorphic ventricular tachycardia associated with a mutation in the cardiac ryanodine receptor gene.
    Nof E; Belhassen B; Arad M; Bhuiyan ZA; Antzelevitch C; Rosso R; Fogelman R; Luria D; El-Ani D; Mannens MM; Viskin S; Eldar M; Wilde AA; Glikson M
    Heart Rhythm; 2011 Oct; 8(10):1546-52. PubMed ID: 21699856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Description of a novel RyR2 mutation in a juvenile patient with symptomatic catecholaminergic polymorphic ventricular tachycardia in sleep and during exercise: a case report.
    Seidlmayer LK; Riediger F; Pagonas N; Nordbeck P; Ritter O; Sasko B
    J Med Case Rep; 2018 Oct; 12(1):298. PubMed ID: 30296944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-Phenotype of Left Ventricular Non-Compaction Cardiomyopathy and Atypical Catecholaminergic Polymorphic Ventricular Tachycardia in Association With R169Q, a Ryanodine Receptor Type 2 Missense Mutation.
    Nozaki Y; Kato Y; Uike K; Yamamura K; Kikuchi M; Yasuda M; Ohno S; Horie M; Murayama T; Kurebayashi N; Horigome H
    Circ J; 2020 Jan; 84(2):226-234. PubMed ID: 31875585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A delayed diagnosis of catecholaminergic polymorphic ventricular tachycardia with a mutant of RYR2 at c.7580T>G for 6 years in a 9-year-old child.
    Duan H; Lu Y; Yan S; Qiao L; Hua Y; Li Y; Zhou K; Wang C
    Medicine (Baltimore); 2018 Apr; 97(16):e0368. PubMed ID: 29668588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and Functional Characterization of Ryanodine Receptor 2 Variants Implicated in Calcium-Release Deficiency Syndrome.
    Roston TM; Wei J; Guo W; Li Y; Zhong X; Wang R; Estillore JP; Peltenburg PJ; Noguer FRI; Till J; Eckhardt LL; Orland KM; Hamilton R; LaPage MJ; Krahn AD; Tadros R; Vinocur JM; Kallas D; Franciosi S; Roberts JD; Wilde AAM; Jensen HK; Sanatani S; Chen SRW
    JAMA Cardiol; 2022 Jan; 7(1):84-92. PubMed ID: 34730774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of flecainide on exercise-induced ventricular arrhythmias and recurrences in genotype-negative patients with catecholaminergic polymorphic ventricular tachycardia.
    Watanabe H; van der Werf C; Roses-Noguer F; Adler A; Sumitomo N; Veltmann C; Rosso R; Bhuiyan ZA; Bikker H; Kannankeril PJ; Horie M; Minamino T; Viskin S; Knollmann BC; Till J; Wilde AA
    Heart Rhythm; 2013 Apr; 10(4):542-7. PubMed ID: 23286974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Familial evaluation in catecholaminergic polymorphic ventricular tachycardia: disease penetrance and expression in cardiac ryanodine receptor mutation-carrying relatives.
    van der Werf C; Nederend I; Hofman N; van Geloven N; Ebink C; Frohn-Mulder IM; Alings AM; Bosker HA; Bracke FA; van den Heuvel F; Waalewijn RA; Bikker H; van Tintelen JP; Bhuiyan ZA; van den Berg MP; Wilde AA
    Circ Arrhythm Electrophysiol; 2012 Aug; 5(4):748-56. PubMed ID: 22787013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nadolol decreases the incidence and severity of ventricular arrhythmias during exercise stress testing compared with β1-selective β-blockers in patients with catecholaminergic polymorphic ventricular tachycardia.
    Leren IS; Saberniak J; Majid E; Haland TF; Edvardsen T; Haugaa KH
    Heart Rhythm; 2016 Feb; 13(2):433-40. PubMed ID: 26432584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arrhythmia characterization and long-term outcomes in catecholaminergic polymorphic ventricular tachycardia.
    Sy RW; Gollob MH; Klein GJ; Yee R; Skanes AC; Gula LJ; Leong-Sit P; Gow RM; Green MS; Birnie DH; Krahn AD
    Heart Rhythm; 2011 Jun; 8(6):864-71. PubMed ID: 21315846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-ventricular, Clinical, and Functional Features of the RyR2(R420Q) Mutation Causing Catecholaminergic Polymorphic Ventricular Tachycardia.
    Domingo D; Neco P; Fernández-Pons E; Zissimopoulos S; Molina P; Olagüe J; Suárez-Mier MP; Lai FA; Gómez AM; Zorio E
    Rev Esp Cardiol (Engl Ed); 2015 May; 68(5):398-407. PubMed ID: 25440180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and molecular characterization of a cardiac ryanodine receptor founder mutation causing catecholaminergic polymorphic ventricular tachycardia.
    Wangüemert F; Bosch Calero C; Pérez C; Campuzano O; Beltran-Alvarez P; Scornik FS; Iglesias A; Berne P; Allegue C; Ruiz Hernandez PM; Brugada J; Pérez GJ; Brugada R
    Heart Rhythm; 2015 Jul; 12(7):1636-43. PubMed ID: 25814417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Recurrent syncope related to catecholaminergic polymorphic ventricular tachycardia due to de novo RyR2-R2401H mutation].
    Liu X; Li JX; Hu JZ; Shen Y; Wan R; Xiong QM; Zhou QQ; Xie JY; Jin JJ; Yan X; Yu JH; Hong K
    Zhonghua Xin Xue Guan Bing Za Zhi; 2017 Jan; 45(1):39-43. PubMed ID: 28100344
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia.
    Priori SG; Napolitano C; Memmi M; Colombi B; Drago F; Gasparini M; DeSimone L; Coltorti F; Bloise R; Keegan R; Cruz Filho FE; Vignati G; Benatar A; DeLogu A
    Circulation; 2002 Jul; 106(1):69-74. PubMed ID: 12093772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ryanodine receptor mutations presenting as idiopathic ventricular fibrillation: a report on two novel familial compound mutations, c.6224T>C and c.13781A>G, with the clinical presentation of idiopathic ventricular fibrillation.
    Paech C; Gebauer RA; Karstedt J; Marschall C; Bollmann A; Husser D
    Pediatr Cardiol; 2014 Dec; 35(8):1437-41. PubMed ID: 24950728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flecainide Reduces Ventricular Arrhythmias in Patients With Genotype RyR2-positive Catecholaminergic Polymorphic Ventricular Tachycardia.
    Wangüemert Pérez F; Hernández Afonso JS; Groba Marco MDV; Caballero Dorta E; Álvarez Acosta L; Campuzano Larrea O; Pérez G; Brugada Terradellas J; Brugada Terradellas R
    Rev Esp Cardiol (Engl Ed); 2018 Mar; 71(3):185-191. PubMed ID: 28789916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sudden death in familial polymorphic ventricular tachycardia associated with calcium release channel (ryanodine receptor) leak.
    Lehnart SE; Wehrens XH; Laitinen PJ; Reiken SR; Deng SX; Cheng Z; Landry DW; Kontula K; Swan H; Marks AR
    Circulation; 2004 Jun; 109(25):3208-14. PubMed ID: 15197150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.